β2-microglobulin and renal bone disease

Peritoneal Dialysis International

Volumn 19, Issue SUPPL. 2, 1999, Pages

  Wada, Takehiko ^a   Miyata, Toshio ^a   Sakai, Hideto ^a   Kurokawa, Kiyoshi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Renal bone disease; 2 microglobulin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID; BETA 2 MICROGLOBULIN; CARBOHYDRATE; LIPID;

AGE; AMYLOIDOSIS; ARTHROPATHY; AUTOOXIDATION; BONE CYST; BONE DISEASE; BONE EROSION; CARPAL TUNNEL SYNDROME; CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIAGNOSTIC IMAGING; DIALYSIS; DIALYSIS MEMBRANE; HEMODIALYSIS; HISTOLOGY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; METABOLISM; PERITONEAL DIALYSIS; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR;

AMYLOID; AMYLOIDOSIS; BETA 2-MICROGLOBULIN; BONE DISEASES; CARPAL TUNNEL SYNDROME; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; JOINT DISEASES; PERITONEAL DIALYSIS; RENAL DIALYSIS; RISK FACTORS;

EID: 0033384695     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901902s67     Document Type: Conference Paper

References (21)

1. 2-microglobulin in renal disease. J Am Soc Nephrol. 1998; 9:1723-35.
2. 2-microglobulin. Biochem Biophys Res Commun. 1985; 129:701-6.
3. 2-microglobulin amyloidosis in haemodialysis: A prospective post-mortem study. Kidney Int. 1997; 51:1928-32.
4. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, et al. β2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest. 1993; 92:1243-52.
5. Miyata T, Taneda S, Kawai R, Ueda Y, Horiuchi S, Hara M, et al. Identification of pentosidine as a native structure for advanced glycation end products in β2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci U S A. 1996; 93:2353-8.
6. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol. 1996; 7:1198-206.
7. Miyata T, Fu MX, Kurokawa K, van Ypersele de Strihou C, Thorpe SR, Baynes JW. Products of autoxidation of both carbohydrates and lipids are increased in uremic plasma. Evidence for a generalized increase in oxidative stress in uremia? Kidney Int. 1998; 54:1290-5.
8. Baynes JW. Perspectives in diabetes: Role of oxidative stress in development of complications in diabetes. Diabetes. 1991; 40:405-12.
9. Miyata T, Maeda K, Kurokawa K, van Ypersele de Strihou C. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant. 1997; 12:255-8.
10. Roselaar SE, Nazhat NB, Winyard PG, Jones P, Cunningham J, Blake DR. Detection of oxidant in uremic plasma by electron spin resonance spectroscopy. Kidney Int. 1995; 48:199-206.
11. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AN, Zingraff I, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996; 49:1304-13.
12. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int. 1997; 51:1170-81.
13. Esterbauer H, Schuer RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehyde. Free Radic Biol Med. 1991; 11:81-128.
14. 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int. 1996; 49:861-7.
15. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in non-enzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int. 1999; 55:389-99.
16. Miyata T, Ueda Y, Yasuda Y, Izuhara Y, Saito A, Jadoul M, et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: Carbonyl stress in uremia. J Am Soc Nephrol. 1998; 9:2349-56.
17. 2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: Implication for the pathogenesis of dialysis-related amyloidosis. J Clin Invest. 1996; 98: 1088-94.
18. 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis: Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin-1. J Clin Invest. 1994; 93:521-8.
19. 2-microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: Role in the pathogenesis hemodialysis-associated amyloidosis. Biochem Biophys Res Commun. 1994; 201:1235-41.
20. 2-microglobulin modified with the advanced glycation end products. Kidney Int. 1996; 49:538-50.
21. Miyata T, Notoya K, Yoshida K, Horie K, Kurokawa K, Maeda K, et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol. 1997; 8:260-70.